Announced Fri, 21 Aug, 2026 · 16:21 IST
Q1 FY27 transcript: revenue up 22%, EBITDA up 27%, service guide INR90-100cr
Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
QMSMEDI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹148.39
prior close
₹150.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.0+2.0+2.1+2.4+0.4+3.1+2.8+4.0+4.8+6.5+11.8+29.4——
Up moveDown movePending
AI summary
Q1 FY27 earnings call transcript filed. Consolidated revenue INR56.9cr, up 22% YoY. EBITDA INR8.3cr, up 27% YoY, margin expanded to 14.6% from 14.1%. PAT INR4cr, up 25% YoY. PSP revenue INR17.6cr, B2B camps 11,497. Migrated to NSE main board on June 18, 2026. Plans to acquire remaining 24% stake in Saarathi Healthcare by Q2 FY27 end. FY27 guidance maintained: revenue around INR220cr, EBITDA margin 18%, service revenue INR90-100cr, PSP revenue INR100-105cr.
Likely market impact
Strong quarter with revenue, EBITDA and PAT all growing faster than last year. Margin expansion and main board migration support a positive view.